NCT06557278: A trial that was reported late by Mirror Biologics, Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT06557278 |
|---|---|
| Title | Phase II Open-Label Study to Assess the Safety and Efficacy of AlloStim® + Anti-PDL1 as Fourth Line Therapy in 4L MSS Metastatic Colorectal Cancer |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 30, 2024 |
| Completion date | June 30, 2025 |
| Required reporting date | June 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 24, 2025 |
| Days late | None |